Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 30, 2025Exploration of MedicineOpen Access

Solid tumor rejection using personalized incompatible human leukocyte antigen (HLA) and blood group ABH antigens

View Full Paper
Ask AI
Bookmark
Share

Authors

AGApostolos P. GeorgopoulosLJLisa M James

Discussion

Loading...

Member takes

Overview

Review highlights cancer immunotherapies and proposes a novel approach using incompatible HLA and blood group antigens for tumor rejection, suggesting a new direction in cancer treatment.

Key Points

  • Tumor rejection is facilitated through novel cancer immunotherapy approaches.
  • The proposed approach leverages incompatibility of HLA and blood group antigens, aiming to enhance immune responses.
  • This strategy compares tumors to organ transplants, where incompatibilities could spur rejection mechanisms.
  • Significantly, the proposed methods may overcome tumor immunoevasion, indicating important treatment potential.

Cite This Study

Georgopoulos et al. (2025) studied this question.

synapsesocial.com/papers/692b9da91d383f2b2a37a41fhttps://doi.org/10.37349/emed.2025.1001375
View Full Paper
Ask AI
Bookmark
Share